Clinical Trial Results and Potential New Drug Application Resubmission Expected in the Second Half of 2024
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/3/2024 | $10.00 | Perform → Outperform | Oppenheimer |
| 4/2/2024 | $10.00 | Buy | H.C. Wainwright |
| 4/27/2022 | $15.00 | Buy | H.C. Wainwright |
| 12/21/2021 | $25.00 → $21.00 | Buy | Citigroup |
| 12/21/2021 | $24.00 → $15.00 | Outperform | SVB Leerink |
8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
10-Q - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
Clinical Trial Results and Potential New Drug Application Resubmission Expected in the Second Half of 2024
Oppenheimer analyst Francois Brisebois reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Outperform and maintains $10 price target.
PDUFA Date is April 2, 2025 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025. In conjunction with the acceptance of the NDA for review, Aldeyra announced the expansion of its exclusive option agreement with AbbVie Inc. (AbbVie). "Based on the FDA's acceptance of the NDA resubmission of reproxalap for dry eye disease for review, we
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference 2024. The conference is being conducted in London, England November 19- 21, 2024. Dr. Brady's conversation with Kelly Shi, Ph.D., Senior Vice President, Biotechnology Equity Research at Jefferies LLC., is scheduled to begin at 12:30 p.m. GMT Thursday, November 21, 2024. To view the live webcast, log in to the Investors & Media secti
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Tomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present at the Disruptive Innovations Symposium during the Ocular Surgery News (OSN) New York Retina 2024 Meeting, which takes place in New York, New York November 8-10, 2024. Dr. Stryjewski will provide an overview of the Phase 2/3 clinical development of ADX-2191 in retinitis pigmentosa. The session will run from 3:30 – 5:30 p.m. ET on Friday, November 8, 2024. About Aldeyra Aldeyra Therapeutics is a biotechnology
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
3 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)
SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)
SC 13G - Aldeyra Therapeutics, Inc. (0001341235) (Subject)
Oppenheimer upgraded Aldeyra Therapeutics from Perform to Outperform and set a new price target of $10.00
H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $10.00
H.C. Wainwright resumed coverage of Aldeyra Therapeutics with a rating of Buy and set a new price target of $15.00
New Drug Application Resubmission Anticipated in 2024 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. Reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort (P=0.004), a U.S. Food and Drug Administration (FDA)-accepted symptom of dry e
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, August 8, 2024, at 9:00 a.m. (ET) to provide top-line results from the Phase 3 dry eye disease clinical trial of reproxalap. The dial-in numbers are (888) 596-4144 for domestic callers and (646) 968-2525 for international callers. The access code is 7321123. A live audio webcast of the conference call also will be accessible from the "Investors & Media" section of Aldeyra's website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyra's website for 90 days. About Aldeyra Aldeyra Therapeutics is a biotechnology company devoted to di
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable resubmission of a New Drug Application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease to the U.S. Food and Drug Administration (FDA). Following discussions with the FDA, Aldeyra intends to initiate a dry eye chamber clinical trial in the first half of 2024. Contingent on positive results from the planned clinical trial, NDA resubmission is expected in the second half of 2